换一批Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.
第一作者：
A L,Harris
第一单位：
Imperial Cancer Research Fund, Molecular Oncology Laboratories, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom. aharris.lab@icrf.icnet.uk
作者：
医学主题词
抗肿瘤药(Antineoplastic Agents);结合部位(Binding Sites);酶联免疫吸附测定(Enzyme-Linked Immunosorbent Assay);女(雌)性(Female);人类(Humans);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);多元分析(Multivariate Analysis);新生血管化, 病理性(Neovascularization, Pathologic);预后(Prognosis);原癌基因蛋白质类(Proto-Oncogene Proteins);丙亚胺(Razoxane);受体蛋白质酪氨酸激酶类(Receptor Protein-Tyrosine Kinases);受体, TIE-2(Receptor, TIE-2);溶解度(Solubility);存活率分析(Survival Analysis);治疗结果(Treatment Outcome);血管内皮生长因子受体1(Vascular Endothelial Growth Factor Receptor-1)
PMID
11448916
发布时间
2013-11-21
- 浏览16
Clinical cancer research
1992-7页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
